GLP‑1 drugs like Ozempic and Mounjaro reshape India’s weight‑loss landscape
Fast facts
- Category: Asia
- Language: EN
- Published: 2026-05-01 22:54 UTC
- Sources: The Hindu
The rise of GLP‑1 medications in India is reframing obesity as a chronic medical condition while sparking debates over access, potential misuse, and the impact on the body‑positivity movement. Critics warn that the drugs could intensify societal pressure to achieve thinness.
Why it matters
- This update can influence the Asia agenda over the next 24-48 hours.
- It is based on 1 source, which helps cross-check key claims quickly.
- Watch follow-up statements and market/public response to assess real impact.